Last patient enrolled in study evaluating the efficacy of MODIA in combination with sublingual buprenorphine/ naloxone for the treatment of OUD
UPPSALA, Sweden, Oct. 28, 2022. Orexo AB (publ.), today announces the last participant has enrolled in the pivotal study of the digital therapeutic MODIA as part of a clinician supervised medication-assisted treatment program for the treatment of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 28, 2022 Category: Pharmaceuticals Source Type: clinical trials
Aquestive Therapeutics Announces Positive Decision in States ’ Suboxone Antitrust Lawsuit on All Claims
WARREN, N.J., Oct. 24, 2022 -- Aquestive Therapeutics, Inc., a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today that the United States District... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 24, 2022 Category: Pharmaceuticals Source Type: clinical trials
Low-dose Buprenorphine Initiation of Opioid Use Disorder
Condition: Opioid Use Disorder Intervention: Drug: buprenorphine-naloxone Sponsor: Montefiore Medical Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 11, 2022 Category: Research Source Type: clinical trials
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
Conditions: Opioid Use Disorder; Opioid Withdrawal Intervention: Drug: Buprenorphine/naloxone Sponsors: United Health Services Hospitals, Inc.; Binghamton University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 1, 2022 Category: Research Source Type: clinical trials
